Profiling of substrate specificity of SARS-CoV 3CLpro

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Chuck, Chi Pang ^a   Chong, Lin Tat ^a   Chen, Chao ^a   Chow, Hak Fun ^a   Wan, David Chi Cheong ^a   Wong, Kam Bo ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3C LIKE PROTEASE; HISTIDINE; METHIONINE; UNCLASSIFIED DRUG; VIRUS ENZYME; 3C PROTEASES; CYSTEINE PROTEINASE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BETA SHEET; CATALYSIS; CORONAVIRUS INFECTION; ENZYME DEGRADATION; ENZYME SPECIFICITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HYDROPHOBICITY; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; SARS CORONAVIRUS; STATIC ELECTRICITY; ENZYMOLOGY; HYDROLYSIS; METABOLISM;

SARS CORONAVIRUS;

CYSTEINE ENDOPEPTIDASES; FLUORESCENCE RESONANCE ENERGY TRANSFER; HYDROLYSIS; SARS VIRUS; SUBSTRATE SPECIFICITY; VIRAL PROTEINS;

EID: 78049266800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013197     Document Type: Article

References (26)

1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.
2. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325.
3. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, et al. (2003) The Genome sequence of the SARS-associated coronavirus. Science 300: 1399-1404.
4. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, et al. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-1399.
5. Chen L, Gui C, Luo X, Yang Q, Gunther S, et al. (2005) Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol 79: 7095-7103.
6. Kao RY, To AP, Ng LW, Tsui WH, Lee TS, et al. (2004) Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. FEBS Lett 576: 325-330.
7. Li SY, Chen C, Zhang HQ, Guo HY, Wang H, et al. (2005) Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 67: 18-23.
8. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, et al. (2004) Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A 101: 10012-10017.
9. Hsu MF, Kuo CJ, Chang KT, Chang HC, Chou CC, et al. (2005) Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 280: 31257-31266.
10. Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E (2004) Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43: 4906-4912.
11. Yang H, Yang M, Ding Y, Liu Y, Lou Z, et al. (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A 100: 13190-13195.
12. Chen S, Chen LL, Luo HB, Sun T, Chen J, et al. (2005) Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique. Acta Pharmacol Sin 26: 99-106.
13. Shi J, Wei Z, Song J (2004) Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem 279: 24765-24773.
14. Hegyi A, Ziebuhr J (2002) Conservation of substrate specificities among coronavirus main proteases. J Gen Virol 83: 595-599.
15. Thiel V, Ivanov KA, Putics A, Hertzig T, Schelle B, et al. (2003) Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol 84: 2305-2315.
16. Fan K, Ma L, Han X, Liang H, Wei P, et al. (2005) The substrate specificity of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun 329: 934-940.
17. Akaji K, Konno H, Onozuka M, Makino A, Saito H, et al. (2008) Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant. Bioorg Med Chem 16: 9400-9408.
18. Chu LH, Choy WY, Tsai SN, Rao Z, Ngai SM (2006) Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Protein Sci 15: 699-709.
19. Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M, et al. (2007) Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry 46: 8744-8752.
20. Lee S, Tikhomirova A, Shalvardjian N, Chalikian TV (2008) Partial molar volumes and adiabatic compressibilities of unfolded protein states. Biophys Chem 134: 185-199.
21. Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157: 105-132.
22. Chou PY, Fasman GD (1978) Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 47: 45-148.
23. Xue X, Yu H, Yang H, Xue F, Wu Z, et al. (2008) Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol 82: 2515-2527.
24. Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
25. Phakthanakanok K, Ratanakhanokchai K, Kyu KL, Sompornpisut P, Watts A, et al. (2009) A computational analysis of SARS cysteine proteinase-octapeptide substrate interaction: implication for structure and active site binding mechanism. BMC Bioinformatics 10 Suppl 1: S48.
26. Tsui SK, Chim SS, Lo YM (2003) Coronavirus genomic-sequence variations and the epidemiology of the severe acute respiratory syndrome. N Engl J Med 349: 187-188.